Named on one round in the feed.
Since 2023-02-21
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Hemab Therapeutics Hemab develops targeted therapies for bleeding disorders, focusing on conditions like Glanzmann Thrombasthenia and Von Willebrand Disease. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $135M | 2023-02-21 | [ PART ] |